Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immuno...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramona Erber, Sareetha Kailayangiri, Hanna Huebner, Matthias Ruebner, Arndt Hartmann, Lothar Häberle, Julia Meyer, Simon Völkl, Andreas Mackensen, Laura Landgraf, Carol I. Geppert, Rüdiger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching, Nicole Farwick, Claudia Rossig, Paul Gass
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	GD2 breast cancer immunofluorescence immunohistochemistry prognosis disialoganglioside Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/559414f8e53e4331963a4808b821cd01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:559414f8e53e4331963a4808b821cd01
record_format	dspace
spelling	oai:doaj.org-article:559414f8e53e4331963a4808b821cd012021-11-11T15:35:48ZVariable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes10.3390/cancers132155772072-6694https://doaj.org/article/559414f8e53e4331963a4808b821cd012021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5577https://doaj.org/toc/2072-6694The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays (TMAs), and its impact on survival. GD2 expression on IHC (<i>n</i> = 568) and IF (<i>n</i> = 503) was investigated in relation to subtypes and patient outcome. Overall, 50.2% of the 568 IHC-assessed samples and 69.8% of the 503 IF-assessed samples were GD2-positive. The highest proportion of GD2-positive tumors was observed in luminal tumors. Significantly fewer GD2-positive cases were detected in triple-negative breast cancer (TNBC) compared with other subtypes. The proportion of GD2-expressing tumors were significantly lower in HER2-positive breast cancer in comparison with luminal tumors on IF staining (but not IHC). GD2 expression of IHC or IF was not significantly associated with disease-free or overall survival, in either the overall cohort or in individual subtypes. However, GD2 expression can be seen in more than 50% of breast cancer cases, with the highest frequency in hormone receptor-positive tumors. With this high expression frequency, patients with GD2-positive advanced breast cancer of all subtypes may benefit from GD2-targeting immunotherapies, which are currently subject to clinical testing.Ramona ErberSareetha KailayangiriHanna HuebnerMatthias RuebnerArndt HartmannLothar HäberleJulia MeyerSimon VölklAndreas MackensenLaura LandgrafCarol I. GeppertRüdiger Schulz-WendtlandMatthias W. BeckmannPeter A. FaschingNicole FarwickClaudia RossigPaul GassMDPI AGarticleGD2breast cancerimmunofluorescenceimmunohistochemistryprognosisdisialogangliosideNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5577, p 5577 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	GD2 breast cancer immunofluorescence immunohistochemistry prognosis disialoganglioside Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	GD2 breast cancer immunofluorescence immunohistochemistry prognosis disialoganglioside Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ramona Erber Sareetha Kailayangiri Hanna Huebner Matthias Ruebner Arndt Hartmann Lothar Häberle Julia Meyer Simon Völkl Andreas Mackensen Laura Landgraf Carol I. Geppert Rüdiger Schulz-Wendtland Matthias W. Beckmann Peter A. Fasching Nicole Farwick Claudia Rossig Paul Gass Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
description	The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays (TMAs), and its impact on survival. GD2 expression on IHC (<i>n</i> = 568) and IF (<i>n</i> = 503) was investigated in relation to subtypes and patient outcome. Overall, 50.2% of the 568 IHC-assessed samples and 69.8% of the 503 IF-assessed samples were GD2-positive. The highest proportion of GD2-positive tumors was observed in luminal tumors. Significantly fewer GD2-positive cases were detected in triple-negative breast cancer (TNBC) compared with other subtypes. The proportion of GD2-expressing tumors were significantly lower in HER2-positive breast cancer in comparison with luminal tumors on IF staining (but not IHC). GD2 expression of IHC or IF was not significantly associated with disease-free or overall survival, in either the overall cohort or in individual subtypes. However, GD2 expression can be seen in more than 50% of breast cancer cases, with the highest frequency in hormone receptor-positive tumors. With this high expression frequency, patients with GD2-positive advanced breast cancer of all subtypes may benefit from GD2-targeting immunotherapies, which are currently subject to clinical testing.
format	article
author	Ramona Erber Sareetha Kailayangiri Hanna Huebner Matthias Ruebner Arndt Hartmann Lothar Häberle Julia Meyer Simon Völkl Andreas Mackensen Laura Landgraf Carol I. Geppert Rüdiger Schulz-Wendtland Matthias W. Beckmann Peter A. Fasching Nicole Farwick Claudia Rossig Paul Gass
author_facet	Ramona Erber Sareetha Kailayangiri Hanna Huebner Matthias Ruebner Arndt Hartmann Lothar Häberle Julia Meyer Simon Völkl Andreas Mackensen Laura Landgraf Carol I. Geppert Rüdiger Schulz-Wendtland Matthias W. Beckmann Peter A. Fasching Nicole Farwick Claudia Rossig Paul Gass
author_sort	Ramona Erber
title	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
title_short	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
title_full	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
title_fullStr	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
title_full_unstemmed	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
title_sort	variable expression of the disialoganglioside gd2 in breast cancer molecular subtypes
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/559414f8e53e4331963a4808b821cd01
work_keys_str_mv	AT ramonaerber variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT sareethakailayangiri variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT hannahuebner variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT matthiasruebner variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT arndthartmann variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT lotharhaberle variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT juliameyer variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT simonvolkl variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT andreasmackensen variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT lauralandgraf variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT caroligeppert variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT rudigerschulzwendtland variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT matthiaswbeckmann variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT peterafasching variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT nicolefarwick variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT claudiarossig variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes AT paulgass variableexpressionofthedisialogangliosidegd2inbreastcancermolecularsubtypes
_version_	1718435178334912512

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

Ejemplares similares